Literature DB >> 17363738

Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia.

Steven M Chan1, Andrew P Weng, Robert Tibshirani, Jon C Aster, Paul J Utz.   

Abstract

Constitutive Notch activation is required for the proliferation of a subgroup of T-cell acute lymphoblastic leukemia (T-ALL). Downstream pathways that transmit pro-oncogenic signals are not well characterized. To identify these pathways, protein microarrays were used to profile the phosphorylation state of 108 epitopes on 82 distinct signaling proteins in a panel of 13 T-cell leukemia cell lines treated with a gamma-secretase inhibitor (GSI) to inhibit Notch signals. The microarray screen detected GSI-induced hypophosphorylation of multiple signaling proteins in the mTOR pathway. This effect was rescued by expression of the intracellular domain of Notch and mimicked by dominant negative MAML1, confirming Notch specificity. Withdrawal of Notch signals prevented stimulation of the mTOR pathway by mitogenic factors. These findings collectively suggest that the mTOR pathway is positively regulated by Notch in T-ALL cells. The effect of GSI on the mTOR pathway was independent of changes in phosphatidylinositol-3 kinase and Akt activity, but was rescued by expression of c-Myc, a direct transcriptional target of Notch, implicating c-Myc as an intermediary between Notch and mTOR. T-ALL cell growth was suppressed in a highly synergistic manner by simultaneous treatment with the mTOR inhibitor rapamycin and GSI, which represents a rational drug combination for treating this aggressive human malignancy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363738      PMCID: PMC1896117          DOI: 10.1182/blood-2006-08-039883

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Significance analysis of microarrays applied to the ionizing radiation response.

Authors:  V G Tusher; R Tibshirani; G Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

2.  Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI.

Authors:  B Raught; A C Gingras; S P Gygi; H Imataka; S Morino; A Gradi; R Aebersold; N Sonenberg
Journal:  EMBO J       Date:  2000-02-01       Impact factor: 11.598

Review 3.  Will mTOR inhibitors make it as cancer drugs?

Authors:  Charles L Sawyers
Journal:  Cancer Cell       Date:  2003-11       Impact factor: 31.743

4.  Notch promotes survival of pre-T cells at the beta-selection checkpoint by regulating cellular metabolism.

Authors:  Maria Ciofani; Juan Carlos Zúñiga-Pflücker
Journal:  Nat Immunol       Date:  2005-07-31       Impact factor: 25.606

5.  Phosphatidic acid-mediated mitogenic activation of mTOR signaling.

Authors:  Y Fang; M Vilella-Bach; R Bachmann; A Flanigan; J Chen
Journal:  Science       Date:  2001-11-30       Impact factor: 47.728

6.  Activating Notch1 mutations in mouse models of T-ALL.

Authors:  Jennifer O'Neil; Jennifer Calvo; Keith McKenna; Veena Krishnamoorthy; Jon C Aster; Craig H Bassing; Frederick W Alt; Michelle Kelliher; A Thomas Look
Journal:  Blood       Date:  2005-09-15       Impact factor: 22.113

7.  Notch activation is an early and critical event during T-Cell leukemogenesis in Ikaros-deficient mice.

Authors:  Alexis Dumortier; Robin Jeannet; Peggy Kirstetter; Eva Kleinmann; MacLean Sellars; Nuno R dos Santos; Christelle Thibault; Jochen Barths; Jacques Ghysdael; Jennifer A Punt; Philippe Kastner; Susan Chan
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

8.  Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis.

Authors:  Diana Bellavia; Antonio F Campese; Saula Checquolo; Anna Balestri; Andrea Biondi; Giovanni Cazzaniga; Urban Lendahl; Hans J Fehling; Adrian C Hayday; Luigi Frati; Harald von Boehmer; Alberto Gulino; Isabella Screpanti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

9.  Pre-TCR-triggered ERK signalling-dependent downregulation of E2A activity in Notch3-induced T-cell lymphoma.

Authors:  Claudio Talora; Antonio F Campese; Diana Bellavia; Monica Pascucci; Saula Checquolo; Manuela Groppioni; Luigi Frati; Harald von Boehmer; Alberto Gulino; Isabella Screpanti
Journal:  EMBO Rep       Date:  2003-10-17       Impact factor: 8.807

10.  Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling.

Authors:  Andrew P Weng; Yunsun Nam; Michael S Wolfe; Warren S Pear; James D Griffin; Stephen C Blacklow; Jon C Aster
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

View more
  122 in total

1.  Canonical Notch signaling is not necessary for prosensory induction in the mouse cochlea: insights from a conditional mutant of RBPjkappa.

Authors:  Martín L Basch; Takahiro Ohyama; Neil Segil; Andrew K Groves
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

2.  Gamma secretase inhibitors enhance vincristine-induced apoptosis in T-ALL in a NOTCH-independent manner.

Authors:  Sun-Ok Yoon; Mariana C Zapata; Akannsha Singh; Wol Soon Jo; Nakia Spencer; Yong Sung Choi
Journal:  Apoptosis       Date:  2014-11       Impact factor: 4.677

3.  Notch signaling regulates gastric antral LGR5 stem cell function.

Authors:  Elise S Demitrack; Gail B Gifford; Theresa M Keeley; Alexis J Carulli; Kelli L VanDussen; Dafydd Thomas; Thomas J Giordano; Zhenyi Liu; Raphael Kopan; Linda C Samuelson
Journal:  EMBO J       Date:  2015-08-12       Impact factor: 11.598

4.  An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.

Authors:  Birgit Knoechel; Justine E Roderick; Kaylyn E Williamson; Jiang Zhu; Jens G Lohr; Matthew J Cotton; Shawn M Gillespie; Daniel Fernandez; Manching Ku; Hongfang Wang; Federica Piccioni; Serena J Silver; Mohit Jain; Daniel Pearson; Michael J Kluk; Christopher J Ott; Leonard D Shultz; Michael A Brehm; Dale L Greiner; Alejandro Gutierrez; Kimberly Stegmaier; Andrew L Kung; David E Root; James E Bradner; Jon C Aster; Michelle A Kelliher; Bradley E Bernstein
Journal:  Nat Genet       Date:  2014-03-02       Impact factor: 38.330

Review 5.  The role of NOTCH1 signaling in T-ALL.

Authors:  Adolfo A Ferrando
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

6.  The Notch Ligand Jagged1 Is Required for the Formation, Maintenance, and Survival of Hensen's Cells in the Mouse Cochlea.

Authors:  Elena Chrysostomou; Luyi Zhou; Yuanzhao L Darcy; Kaley A Graves; Angelika Doetzlhofer; Brandon C Cox
Journal:  J Neurosci       Date:  2020-10-30       Impact factor: 6.167

7.  gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity.

Authors:  Raymond D Meng; Christopher C Shelton; Yue-Ming Li; Li-Xuan Qin; Daniel Notterman; Philip B Paty; Gary K Schwartz
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

8.  K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

Authors:  Thomas Kindler; Melanie G Cornejo; Claudia Scholl; Jianing Liu; Dena S Leeman; J Erika Haydu; Stefan Fröhling; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2008-07-28       Impact factor: 22.113

9.  Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.

Authors:  J Tammam; C Ware; C Efferson; J O'Neil; S Rao; X Qu; J Gorenstein; M Angagaw; H Kim; C Kenific; K Kunii; K J Leach; G Nikov; J Zhao; X Dai; J Hardwick; M Scott; C Winter; L Bristow; C Elbi; J F Reilly; T Look; G Draetta; Lht Van der Ploeg; N E Kohl; P R Strack; P K Majumder
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

Review 10.  Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.

Authors:  Teresa Palomero; Adolfo Ferrando
Journal:  Clin Lymphoma Myeloma       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.